Page 35 - Read Online

Lee Cell-mediated immunotherapy for HCC

35. O’Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.
O’Donnell DM, Kay E, O’Connell F, Gallagher WM, O’Byrne KJ. 51. Qiu Y, Xu MB, Yun MM, Wang YZ, Zhang RM, Meng XK, Ou-Yang
Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in XH, Yun S. Hepatocellular carcinoma-specific immunotherapy with
nonsmall cell lung cancer. Eur Respir J 2015;46:1762-72. synthesized alpha1,3- galactosyl epitope-pulsed dendritic cells and
36. Lee WC, Wu TJ, Chou HS, Yu MC, Hsu PY, Hsu HY, Wang CC. The cytokine-induced killer cells. World J Gastroenterol 2011;17:5260-6.
impact of CD4+ CD25+ T cells in the tumor microenvironment of 52. Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Arai
hepatocellular carcinoma. Surgery 2012;151:213-22. K, Yamashita T, Yokoyama K, Mukaida N, Matsushima K,
37. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand- Matsui O, Kaneko S. Combined therapy of transcatheter hepatic
Rosenberg S, Schreiber H. The terminology issue for myeloid-derived arterial embolization with intratumoral dendritic cell infusion
suppressor cells. Cancer Res 2007;67:425; author reply 426. for hepatocellular carcinoma: clinical safety. Clin Exp Immunol
38. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, 2007;147:296-305.
Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. 53. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda
Identification of discrete tumor-induced myeloid-derived suppressor E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte
cell subpopulations with distinct T cell-suppressive activity. Blood JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-
2008;111:4233-44. 4 blockade with tremelimumab in patients with hepatocellular
39. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset 54. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim
definition. Curr Opin Immunol 2010;22:238-44. TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W,
40. Ueha S, Shand FH, Matsushima K. Myeloid cell population Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani
dynamics in healthy and tumor-bearing mice. Int Immunopharmacol HB, Melero I. Nivolumab in patients with advanced hepatocellular
2011;11:783-8. carcinoma (CheckMate 040): an open-label, non-comparative, phase
41. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
Finke JH, Cohen PA. Direct and differential suppression of myeloid- 55. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr
derived suppressor cell subsets by sunitinib is compartmentally Opin Immunol 2010;22:251-7.
constrained. Cancer Res 2010;70:3526-36. 56. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T,
42. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y,
M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence
inhibitor in the reversal of immune suppression and modulation of rates of hepatocellular carcinoma: a randomised trial. Lancet
tumor microenvironment for immune-based cancer therapies. Cancer 2000;356:802-7.
Res 2009;69:2514-22. 57. Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan
43. Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S. Generation of QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE,
antigen-presenting cells from tumor-infiltrated CD11b myeloid cells Li Q, Xia JC. A phase I clinical trial utilizing autologous tumor-
with DNA demethylating agent 5-aza-2’-deoxycytidine. Cancer infiltratinglymphocytes in patients with primary hepatocellular
Immunol Immunother 2010;59:697-706. carcinoma. Oncotarget 2015;6:41339-49.
44. Gabrilovich DI. Combination of chemotherapy and immunotherapy 58. Shi M, Bing Zhang, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP,
for cancer: a paradigm revisited. Lancet Oncol 2007;8:2-3. Xu DP, Wang FS. Autologous cytokine-induced killer cell therapy
45. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, in clinical trial phaseI is safe in patients with primary hepatocellular
Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid carcinoma. World J Gastroenterol 2004;10:1146-51.
cells from tumor-bearing mice and improves the effect of vaccination. 59. Hao M, Lin H, Chen Q, Ye YB, Chen QZ, Chen MS. Efficacy
Cancer Res 2003;63:4441-9. of transcatheter arterial chemoembolizationcombined with
46. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, cytokineinduced killer cell therapy onhepatocellular carcinoma: a
Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, comparative study. Chin J Cancer 2010;29:172-7.
Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing 60. Su Y, Yang Y, Ma Y, Zhang Y, Rao W, Yang G, Kou C. The efficacy
hosts and promotes tumor eradication by cancer vaccination. Proc and safety of dendritic cells co-cultured with cytokine-induced killer
Natl Acad Sci U S A 2005;102:4185-90. cell therapy in combination with TACE-predominant minimally-
47. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine invasive treatment for hepatocellular carcinoma: a meta-analysis. Clin
selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor Lab 2016;62:599-608.
cells in tumor-bearing animals and enhances antitumor immune 61. Hong Y, Huang J. Autoantibodies against tumor-associated antigens for
activity. Clin Cancer Res 2005;11:6713-21. detection of hepatocellular carcinoma. World J Hepatol 2015;7:1581-
48. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush 5.
RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves 62. Sun Z, Zhu Y, Xia J, Sawakami T, Kokudo N, Zhang N. Status of
differentiation of myeloid cells and immune response in cancer and prospects for cancer vaccines against hepatocellular carcinoma in
patients. Cancer Res 2006;66:9299-307. clinical trials. Biosci Trends 2016;10:85-91.
49. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, 63. Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht
Kawano K, Kitano S. A phase I study of autologous dendritic cell- N, Ouyang Y, Cornforth AN, Jadus MR. HCA519/TPX2: a potential
based immunotherapy for patients with unresectable primary liver T-cell tumor-associated antigen for human hepatocellular carcinoma.
cancer. Cancer Immunol Immunother 2003;52:155-61. Onco Targets Ther 2014;7:1061-70.
50. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven 64. Zhu Z, Liu Z, Liu Y, Wang C, Li R, Liu H, Gu B, Li G, Zhang S.
NM, Kerr DJ, Young LS, Adams DH. A phase II study of adoptive Screening and identification of the tumor-associated antigen CK10, a
immunotherapy using dendritic cells pulsed with tumor lysate in novel potential liver cancer marker. FEBS Open Bio 2017;7:627-35.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ October 31, 2017 249